{{Rsnum
|rsid=334558
|Gene=GSK3B
|Chromosome=3
|position=120094435
|Orientation=plus
|GMAF=0.4747
|Gene_s=GSK3B,LOC100996310
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 0.0 | 0.0
| HCB | 0.0 | 60.5 | 39.5
| JPT | 11.4 | 25.7 | 62.9
| YRI | 0.0 | 1.6 | 98.4
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 60.5 | 39.5
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}Although not associated with increased risk for developing [[bipolar disorder]], amongst those with it, the (G) allele of this SNP has been reported to have a somewhat protective effect in that individuals who have a (G) allele develop [[bipolar disorder]] at a later age than those with the more common (A;A) genotypes. [PMID 15351432, PMID 14729229]

Also known as the -50T/C SNP from this GSK3-beta ([[GSK3B]]) gene.

may effect [[lithium]] treatment response - {{PMID|17628506}} C allele carriers showed considerably greater response with lithium treatment, with remissions of 56.25% after 4 weeks compared to 31% for T/T carriers

{{PMID Auto
|PMID=19573950
|Title=GSK3beta polymorphisms, MAPT H1 haplotype and Parkinson's disease in a Greek cohort
}}

{{omim
|desc=GLYCOGEN SYNTHASE KINASE 3-BETA; GSK3B
|id=605004
|rsnum=334558
}}

{{PharmGKB
|RSID=rs334558
|Name_s=GSK3B: -50 T>C
|Gene_s=GSK3B
|Feature=
|Evidence=PubMed ID:16315267; PubMed ID:18195729
|Annotation=This variant is in the promoter region of GSK3B. T allele is associated with greater transcription activity compared with the A allele. This variant is associated with antidepressant treatment response in Chinese major depressive disorder. In a four-locus haplotype analysis (rs334558; rs13321783; rs2319398; rs6808874), the GSK3B TAGT carriers showed a poorer response to antidepressants than carriers with other haplotype groups.
|Drugs=citalopram; fluoxetine
|Drug Classes=
|Diseases=Depression; Depressive Disorder, Major; Parkinsonian Disorders
|Curation Level=Curated
|PharmGKB Accession ID=PA162369928
}}

{{PMID Auto
|PMID=20055739
|Title=Role of glycogen synthase kinase 3 (GSK-3) in innate immune response of human immature dendritic cells to Aspergillus fumigatus
}}
{{PMID Auto
|PMID=21159074
|Title=SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study
}}

{{PMID Auto
|PMID=22119086
|Title=Gene-gene interaction of glycogen synthase kinase 3-? and serotonin transporter on human antidepressant response to sleep deprivation
}}

{{PMID Auto
|PMID=22815195
|Title=GSK3β reduces risk of sporadic Parkinson's disease in ethnic Chinese
}}

{{PMID Auto
|PMID=19154537
|Title=Epistasis between tau phosphorylation regulating genes (CDK5R1 and GSK-3beta) and Alzheimer's disease risk.
}}

{{PMID Auto
|PMID=20113358
|Title=Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-beta activity.
}}

{{PMID Auto
|PMID=21443865
|Title=Association analysis of GSK3B and MAPT polymorphisms with Alzheimer's disease in Han Chinese.
}}

{{PMID Auto
|PMID=21527318
|Title=GSK3beta genetic variability in patients with Multiple Sclerosis.
}}

{{PMID Auto
|PMID=23021822
|Title=Glycogen synthase kinase 3β gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs334558
|overall_frequency_n=46
|overall_frequency_d=84
|overall_frequency=0.547619
|n_genomes=24
|n_genomes_annotated=0
|n_haplomes=39
|n_articles=0
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23440732
|Title=GSK-3β Polymorphism Discriminates Bipolar Disorder and Schizophrenia: A Systematic Meta-Analysis
}}

{{PMID Auto
|PMID=21130530
|Title=Role of tau kinases (CDK5R1 and GSK3B) in Parkinson's disease: a study from India
}}

{{PMID Auto
|PMID=22990942
|Title=Lithium and GSK3-beta promoter gene variants influence white matter microstructure in bipolar disorder.
|OA=1
}}

{{PMID Auto
|PMID=23030648
|Title=Possible association of the GSK3beta gene with the anxiety symptoms of major depressive disorder and P300 waveform.
|OA=1
}}

{{PMID Auto
|PMID=23628795
|Title=The association between glycogen synthase kinase 3 beta polymorphisms and Parkinson's disease susceptibility: a meta-analysis.
}}

{{PMID Auto
|PMID=24929537
|Title=Meta-analysis demonstrates lack of association of the GSK3B -50C/T polymorphism with risk of bipolar disorder
}}

{{PMID Auto
|PMID=24779391
|Title=MAPT rs242562 and GSK3B rs334558 are associated with Parkinson's Disease in central China
}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}